key: cord-1035452-z3bow7mp
authors: Cavanna, Luigi; Citterio, Chiara; Cattadori, Evelina; Bosi, Costanza; Caprioli, Serena
title: Re: The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey
date: 2021-09-25
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.07.048
sha: ca2956d5574b7e78048133ae76b0f5ab77d75f4f
doc_id: 1035452
cord_uid: z3bow7mp

nan

We read with interest the study reported by Di Noia and colleagues [1] in the August issue of European Journal of Cancer about adherence to SARS-COV-2 vaccine, entitled "The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey".

All candidate cancer patients were offered the BNT162b2 vaccine by phone contact or during scheduled visits, with 102 (11.2%) of the 914 eligible patients refusing vaccination. The most frequently given reasons were concerns about possible adverse events (48.1%), suspicions over negative interactions with ongoing anticancer treatments (26.7%), or previous allergic reactions (10.7%). These data differ substantially from the experience of our Oncology and Hematology Department where only three (0.68%) of 443 eligible cancer patients with advanced active disease and on systemic antitumor treatment, or who had received treatment within the last six months, refused vaccination.

We would like to offer some explanation for the varying rates of adherence among cancer patients in the same country, albeit in different areas of northern and south-central Italy in Piacenza and Rome, respectively.

Italy was the first country after China to be affected by the pandemic and our city, Piacenza, is close to the epicenter of the outbreak in Italy being just 10 minutes away by car. Many oncology patients from that area were actively receiving treatment at our hospital. Some became infected by COVID-19 and many of them died. We previously reported the first 25 cancer patients with COVID-19 pneumonia in the Western world, finding a mortality rate of 36.00% [2] . Subsequently, we reported cases involving 51 cancer patients with COVID-19 and found a mortality rate of 23.53% [3] .

Vaccines BNT162b2 and mRNA-1273 were approved [4] and recommended by both the United States Food and Drug Administration and the European Medicines Agency to prevent COVID-19 disease. However, there is a paucity of data on the efficacy and safety of mRNA COVID-19 vaccines in cancer patients in terms of their antibody-mediated response and tolerability.

We engaged the local community of cancer patients and used TV and radio campaigns as well as the social media presence of various volunteers to promote the importance of COVID-19 vaccines for oncology patients. In addition, a vaccine task force composed of nurses, oncologists, and psychologists was established in our department. All 443 cancer patients who were eligible for COVID-19 vaccination were contacted by phone and given information about the benefits and risks from the reference oncologist and nurse after which 394 immediately accepted the invitation. Of those contacted, 49 (11.06%) were initially dubious about the vaccine but a second conversation with caregivers and the oncologist helped them take the decision to vaccinate. Ultimately, only three (0.68%) of the 443 patients refused vaccination with two citing ideological reasons and one refusing for fear of interference with their cancer and its treatment.

In conclusion, we agree with Curigliano et al. [5] that, given the greater severity of and higher risk of death from COVID-19 in cancer patients, we as healthcare workers need to make every possible effort to improve vaccination adherence by this group. The high adherence to COVD-19 vaccination by oncology patients in our district has been recognized by local health authorities as a model to promote vaccination in other populations [6] . 

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

Coronavirus Disease-2019 in cancer patients. A report of the first 25 cancer patients in a Western country (Italy)

Cancer patients with COVID-19: A retrospective study of 51 patients in the district of Piacenza, Northern Italy

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Adherence to COVID-19 vaccines in cancer patients: Promote it and make it happen!

Malati di tumore, il vaccino è sicuro